

Guillermo L Chantada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6881641/publications.pdf>

Version: 2024-02-01

160
papers

6,021
citations

70961

41
h-index

98622

67
g-index

168
all docs

168
docs citations

168
times ranked

3784
citing authors

#	ARTICLE	IF	CITATIONS
1	Retinoblastoma. Nature Reviews Disease Primers, 2015, 1, 15021.	18.1	376
2	A proposal for an international retinoblastoma staging system. Pediatric Blood and Cancer, 2006, 47, 801-805.	0.8	225
3	Treatment of Retinoblastoma in 2015. JAMA Ophthalmology, 2015, 133, 1341.	1.4	208
4	Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma. Ophthalmology, 2007, 114, 1378-1383.	2.5	201
5	Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncology, 2020, 6, 685.	3.4	192
6	Local and Systemic Toxicity of Intravitreal Melphalan for Vitreous Seeding in Retinoblastoma. Ophthalmology, 2014, 121, 1810-1817.	2.5	147
7	Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. "Alive, with good vision and no comorbidity" Progress in Retinal and Eye Research, 2019, 73, 100764.	7.3	123
8	Retinoblastoma: One World, One Vision. Pediatrics, 2008, 122, e763-e770.	1.0	115
9	Strategies to manage retinoblastoma in developing countries. Pediatric Blood and Cancer, 2011, 56, 341-348.	0.8	115
10	The COVID-19 pandemic: A rapid global response for children with cancer from SIOP, COG, SIOP-EE, SIOP-PODC, IPSO, PROS, CCI, and St Jude Global. Pediatric Blood and Cancer, 2020, 67, e28409.	0.8	113
11	Treatment of overt extraocular retinoblastoma. Medical and Pediatric Oncology, 2003, 40, 158-161.	1.0	111
12	LANGERHANS CELL HISTIOCYTOSIS: Retrospective Evaluation of 123 Patients at a Single Institution. Pediatric Hematology and Oncology, 1999, 16, 377-385.	0.3	96
13	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncology, The, 2021, 22, 1416-1426.	5.1	93
14	Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. The Lancet Child and Adolescent Health, 2021, 5, 332-340.	2.7	83
15	Treatment of retinoblastoma: Current status and future perspectives. Current Treatment Options in Neurology, 2007, 9, 294-307.	0.7	75
16	Outcome in children with pulmonary Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2004, 43, 765-769.	0.8	74
17	SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatric Blood and Cancer, 2015, 62, 1305-1316.	0.8	73
18	Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America. Lancet Oncology, The, 2020, 21, 753-755.	5.1	73

#	ARTICLE	IF	CITATIONS
19	Results of a prospective study for the treatment of retinoblastoma. <i>Cancer</i> , 2004, 100, 834-842.	2.0	69
20	SIOPâ€PODC recommendations for graduatedâ€intensity treatment of retinoblastoma in developing countries. <i>Pediatric Blood and Cancer</i> , 2013, 60, 719-727.	0.8	69
21	Highâ€dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2010, 55, 149-152.	0.8	68
22	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	67
23	Trilateral retinoblastoma: Potentially curable with intensive chemotherapy. <i>Pediatric Blood and Cancer</i> , 2010, 54, 384-387.	0.8	66
24	Practical recommendations for the management of children with Endemic Burkitt Lymphoma (BL) in a resource limited setting. <i>Pediatric Blood and Cancer</i> , 2013, 60, 357-362.	0.8	60
25	Outcome of Patients with Retinoblastoma and Postlaminar Optic Nerve Invasion. <i>Ophthalmology</i> , 2007, 114, 2083-2089.	2.5	59
26	Risk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2007, 49, 256-260.	0.8	57
27	Pharmacokinetic Analysis of Melphalan after Superselective Ophthalmic Artery Infusion in Preclinical Models and Retinoblastoma Patients. , 2012, 53, 4205.		57
28	Topotecan Vitreous Levels after Periocular or Intravenous Delivery in Rabbits: An Alternative for Retinoblastoma Chemotherapy. , 2007, 48, 3761.		54
29	World disparities in risk definition and management of retinoblastoma: A report from the International Retinoblastoma Staging Working Group. <i>Pediatric Blood and Cancer</i> , 2008, 50, 692-694.	0.8	52
30	Reactivation and risk of sequelae in Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2007, 48, 696-699.	0.8	51
31	Results of a prospective study for the treatment of unilateral retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2010, 55, 60-66.	0.8	51
32	Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. <i>Pediatric Blood and Cancer</i> , 2009, 52, 218-222.	0.8	50
33	Outcome of Children With Retinoblastoma and Isolated Choroidal Invasion. <i>JAMA Ophthalmology</i> , 2012, 130, 724-9.	2.6	49
34	Colorectal Carcinoma in Children, Adolescents, and Young Adults. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 39-41.	0.3	48
35	A Phase I Study of Periocular Topotecan in Children with Intraocular Retinoblastoma. , 2009, 50, 1492.		48
36	A framework to develop adapted treatment regimens to manage pediatric cancer in lowâ€and middleâ€income countries: The Pediatric Oncology in Developing Countries (PODC) Committee of the International Pediatric Oncology Society (SIOP). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26879.	0.8	48

#	ARTICLE	IF	CITATIONS
37	Activity of topotecan in retinoblastoma. <i>Ophthalmic Genetics</i> , 2004, 25, 37-43.	0.5	47
38	Some Clinical Findings at Presentation Can Predict High-risk Pathology Features in Unilateral Retinoblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 325-329.	0.3	47
39	Episcleral Implants for Topotecan Delivery to the Posterior Segment of the Eye. , 2010, 51, 2126.		47
40	Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. <i>Pediatric Blood and Cancer</i> , 2005, 44, 455-460.	0.8	46
41	Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 766-770.	0.8	46
42	Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-6.	3.3	45
43	Clinical Pharmacokinetics of Intra-arterial Melphalan and Topotecan Combination in Patients with Retinoblastoma. <i>Ophthalmology</i> , 2014, 121, 889-897.	2.5	45
44	Metastatic deaths in retinoblastoma patients treated with intraarterial chemotherapy (ophthalmic) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.9	45
45	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. <i>Nature Communications</i> , 2021, 12, 5578.	5.8	45
46	Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma. <i>Experimental Eye Research</i> , 2013, 108, 103-109.	1.2	42
47	Children with fever of unknown origin in Argentina. <i>Pediatric Infectious Disease Journal</i> , 1994, 13, 260-263.	1.1	41
48	Global Retinoblastoma Treatment Outcomes. <i>Ophthalmology</i> , 2021, 128, 740-753.	2.5	40
49	Retinoblastoma with low risk for extraocular relapse. <i>Ophthalmic Genetics</i> , 1999, 20, 133-140.	0.5	39
50	Use of intra-arterial chemotherapy for retinoblastoma: results of a survey. <i>International Journal of Ophthalmology</i> , 2014, 7, 726-30.	0.5	39
51	A population-based study of retinoblastoma incidence and survival in Argentine children. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1610-1615.	0.8	38
52	OCULAR PHARMACOLOGY OF TOPOTECAN AND ITS ACTIVITY IN RETINOBLASTOMA. <i>Retina</i> , 2014, 34, 1719-1727.	1.0	38
53	Pharmacokinetic analysis of topotecan after intra-vitreous injection. Implications for retinoblastoma treatment. <i>Experimental Eye Research</i> , 2010, 91, 9-14.	1.2	37
54	A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma. <i>Ophthalmology</i> , 2020, 127, 1733-1746.	2.5	37

#	ARTICLE	IF	CITATIONS
55	XAF1 as a modifier of p53 function and cancer susceptibility. <i>Science Advances</i> , 2020, 6, eaba3231.	4.7	37
56	Familial retinoblastoma in developing countries. <i>Pediatric Blood and Cancer</i> , 2009, 53, 338-342.	0.8	36
57	A Multicenter, International Collaborative Study for American Joint Committee on Cancer Staging of Retinoblastoma. <i>Ophthalmology</i> , 2020, 127, 1719-1732.	2.5	36
58	A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2120-2124.	0.8	34
59	PHARMACOKINETIC ANALYSIS OF TOPOTECAN AFTER SUPERSELECTIVE OPHTHALMIC ARTERY INFUSION AND PERIOcular ADMINISTRATION IN A PORCINE MODEL. <i>Retina</i> , 2012, 32, 387-395.	1.0	33
60	Treatment of Nonmetastatic Unilateral Retinoblastoma in Children. <i>JAMA Ophthalmology</i> , 2018, 136, 747.	1.4	33
61	Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. <i>Journal of Clinical Oncology</i> , 2019, 37, 2875-2882.	0.8	33
62	Title is missing!. , 2017, , .		33
63	Microscopic Scleral Invasion in Retinoblastoma. <i>JAMA Ophthalmology</i> , 2009, 127, 1006.	2.6	32
64	Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. <i>Pediatric Blood and Cancer</i> , 2014, 61, 821-826.	0.8	32
65	Intraocular carboplatin concentrations following intravenous administration for human intraocular retinoblastoma. <i>Ophthalmic Genetics</i> , 1999, 20, 31-36.	0.5	31
66	Management of Retinoblastoma in Children: Current Status. <i>Paediatric Drugs</i> , 2015, 17, 185-198.	1.3	31
67	OCULAR PHARMACOLOGY OF CHEMOTHERAPY FOR RETINOBLASTOMA. <i>Retina</i> , 2017, 37, 1-10.	1.0	31
68	An international survey of classification and treatment choices for group D retinoblastoma. <i>International Journal of Ophthalmology</i> , 2017, 10, 961-967.	0.5	30
69	Treatment of Retinoblastoma: What Is the Latest and What Is the Future. <i>Frontiers in Oncology</i> , 2022, 12, 822330.	1.3	30
70	Phase II Window of Idarubicin in Children With Extraocular Retinoblastoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1847-1847.	0.8	29
71	Retinoblastoma: Lessons and challenges from developing countries. Ellsworth Lecture 2011. <i>Ophthalmic Genetics</i> , 2011, 32, 196-203.	0.5	29
72	Comparison of Staging Systems for Extraocular Retinoblastoma. <i>JAMA Ophthalmology</i> , 2013, 131, 1127.	1.4	29

#	ARTICLE	IF	CITATIONS
73	Association of Cone-Rod Homeobox Transcription Factor Messenger RNA With Pediatric Metastatic Retinoblastoma. <i>JAMA Ophthalmology</i> , 2015, 133, 805.	1.4	28
74	An Aggressive Bone Marrow Evaluation Including Immunocytology With GD2 for Advanced Retinoblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 369-373.	0.3	27
75	Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma. <i>Cancers</i> , 2020, 12, 2714.	1.7	27
76	Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. <i>European Journal of Cancer</i> , 2013, 49, 2892-2899.	1.3	26
77	Immunoreactivity of the 14F7 Mab raised against <i>N</i> -Glycolyl GM ₃ Ganglioside in retinoblastoma tumours. <i>Acta Ophthalmologica</i> , 2015, 93, e294-300.	0.6	26
78	Acute myeloid leukemia as a second malignancy: report of 9 pediatric patients in a single institution in Argentina. , 1998, 30, 160-164.		24
79	Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. <i>Ophthalmology</i> , 2020, 127, 1549-1557.	2.5	24
80	The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. <i>The Lancet Global Health</i> , 2022, 10, e1128-e1140.	2.9	24
81	Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. <i>Cancer Letters</i> , 2016, 380, 10-19.	3.2	22
82	Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina. , 1997, 29, 544-552.		21
83	Web-based survey of resources for treatment and long-term follow-up for children with brain tumors in developing countries. <i>Child's Nervous System</i> , 2011, 27, 1957-1961.	0.6	21
84	Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival. <i>JAMA Ophthalmology</i> , 2016, 134, 1374.	1.4	21
85	Pharmacokinetics of Melphalan After Intravitreal Injection in a Rabbit Model. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2016, 32, 230-235.	0.6	21
86	Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27086.	0.8	21
87	Anterior Segment Invasion in Retinoblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e509-e512.	0.3	20
88	Intensive multi-modality therapy for extra-ocular retinoblastoma (RB): A Children's Oncology Group (COG) trial (ARET0321).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10506-10506.	0.8	20
89	Clinical Presentation of Retinoblastoma in a Middle-income Country. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e97-e101.	0.3	19
90	Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries. <i>British Journal of Ophthalmology</i> , 2021, 105, 1435-1443.	2.1	19

#	ARTICLE	IF	CITATIONS
91	Is It Pre-Enucleation Chemotherapy or Delayed Enucleation of Severely Involved Eyes With Intraocular Retinoblastoma That Risks Extraocular Dissemination and Death?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3333-3334.	0.8	18
92	Pharmacokinetics, Safety, and Efficacy of Intravitreal Digoxin in Preclinical Models for Retinoblastoma. , 2015, 56, 4382.		18
93	Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory risk multisystem Langerhans cell histiocytosis. <i>British Journal of Haematology</i> , 2016, 172, 287-290.	1.2	18
94	Racotumomab for treating lung cancer and pediatric refractory malignancies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 573-578.	1.4	18
95	Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells. <i>PLoS ONE</i> , 2016, 11, e0160094.	1.1	18
96	Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. <i>Molecular Medicine Reports</i> , 2010, 3, 253-9.	1.1	18
97	Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment. <i>British Journal of Haematology</i> , 2019, 185, 1125-1135.	1.2	17
98	Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma. <i>JAMA Ophthalmology</i> , 2020, 138, 569.	1.4	17
99	Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study. <i>Cancer</i> , 2022, 128, 1493-1502.	2.0	17
100	Results of a BFM-based protocol for the treatment of childhood B-non-Hodgkin's lymphoma and B-Acute lymphoblastic leukemia in Argentina. , 1997, 28, 333-341.		16
101	Importance of Multi-lineage Hematologic Involvement and Hypoalbuminemia at Diagnosis in Patients With Risk-organ Multi-system Langerhans Cell Histiocytosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, e122-e125.	0.3	16
102	Sustained-release hydrogels of topotecan for retinoblastoma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 146, 624-631.	2.5	16
103	Spectrum of RB1 Mutations in Argentine Patients: 20-years Experience in the Molecular Diagnosis of Retinoblastoma. <i>Ophthalmic Genetics</i> , 2013, 34, 189-198.	0.5	14
104	Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery. <i>PLoS ONE</i> , 2016, 11, e0151343.	1.1	14
105	Beliefs and Determinants of Use of Traditional Complementary/Alternative Medicine in Pediatric Patients Who Undergo Treatment for Cancer in South America. <i>Journal of Global Oncology</i> , 2017, 3, 701-710.	0.5	14
106	Outcome of pediatric non-Hodgkin lymphoma in Central America: A report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA). <i>Pediatric Blood and Cancer</i> , 2019, 66, e27621.	0.8	14
107	Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia. <i>Leukemia Research</i> , 1996, 20, 973-981.	0.4	13
108	Anaplastic Large Cell Lymphoma in Central America: A Report From the Central American Association of Pediatric Hematology Oncology (AHOPCA). <i>Pediatric Blood and Cancer</i> , 2016, 63, 78-82.	0.8	13

#	ARTICLE	IF	CITATIONS
109	Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in argentina. <i>Medical and Pediatric Oncology</i> , 2003, 41, 488-490.	1.0	12
110	Early Mortality in Children With Advanced Mature B-cell Malignancies in a Middle-income Country. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e266-e270.	0.3	12
111	Improving our understanding of the use of traditional complementary/alternative medicine in children with cancer. <i>Cancer</i> , 2015, 121, 1492-1498.	2.0	11
112	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. <i>Journal of Controlled Release</i> , 2017, 264, 34-44.	4.8	11
113	The technique of superselective ophthalmic artery chemotherapy for retinoblastoma: The Garrahan Hospital experience. <i>Interventional Neuroradiology</i> , 2018, 24, 93-99.	0.7	11
114	Combined high-dose intra-arterial and intrathecal chemotherapy for the treatment of a case of extraocular retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27385.	0.8	11
115	A decision process for drug discovery in retinoblastoma. <i>Investigational New Drugs</i> , 2021, 39, 426-441.	1.2	11
116	Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). <i>Journal of Clinical Oncology</i> , 2022, 40, 3839-3847.	0.8	11
117	Assessment of retinoblastoma RNA reflux after intravitreal injection of melphalan. <i>British Journal of Ophthalmology</i> , 2018, 102, 415-418.	2.1	10
118	Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina. <i>Ecancermedicalsecience</i> , 2016, 10, 672.	0.6	9
119	Twenty-Year Collaboration Between North American and South American Retinoblastoma Programs. <i>Journal of Global Oncology</i> , 2016, 2, 347-352.	0.5	9
120	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. <i>Cancers</i> , 2021, 13, 673.	1.7	9
121	Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28963.	0.8	9
122	Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries. <i>Eye</i> , 2022, 36, 1571-1577.	1.1	9
123	COVID-19: Consequences for Children With Cancer in Turkey and Globally. , 2021, 56, 295-299.		9
124	Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging. <i>British Journal of Ophthalmology</i> , 2023, 107, 127-132.	2.1	9
125	Defining High-risk Retinoblastoma. <i>JAMA Ophthalmology</i> , 2022, 140, 30.	1.4	9
126	High-risk Pathologic Features Based on Presenting Findings in Advanced Intraocular Retinoblastoma. <i>Ophthalmology</i> , 2022, 129, 923-932.	2.5	9

#	ARTICLE	IF	CITATIONS
127	The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28962.	0.8	8
128	Metastatic Death Based on Presenting Features and Treatment for Advanced Intraocular Retinoblastoma. <i>Ophthalmology</i> , 2022, 129, 933-945.	2.5	8
129	Staging and grouping of retinoblastoma. , 2007, , 422-427.		7
130	Lack of activity of oral etoposide for relapsed intraocular retinoblastoma. <i>Ophthalmic Genetics</i> , 2004, 25, 25-29.	0.5	6
131	Response criteria for intraocular retinoblastoma: RB-RECIST. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28964.	0.8	6
132	Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29568.	0.8	6
133	Subsequent malignant neoplasms in the pediatric age in retinoblastoma survivors in Argentina. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29710.	0.8	6
134	Metronomic Chemotherapy for Children in Low- and Middle-Income Countries: Survey of Current Practices and Opinions of Pediatric Oncologists. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	5
135	Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG). <i>Cancers</i> , 2021, 13, 3392.	1.7	5
136	Impact of COVID-19 in pediatric oncology care in Latin America during the first year of the pandemic. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29748.	0.8	5
137	Alkalinization and tumor lysis syndrome. , 1999, 32, 156-156.		4
138	Trisomy 3 in two paediatric post-transplant lymphomas. <i>British Journal of Haematology</i> , 2002, 117, 558-562.	1.2	4
139	Ophthalmic Artery Microcatheterization for Research Purposes in Pigs. A Technical Note. <i>Journal of Investigative Surgery</i> , 2014, 27, 291-293.	0.6	4
140	Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma. <i>British Journal of Ophthalmology</i> , 2018, 102, 1597-1601.	2.1	4
141	The threat of the COVID-19 pandemic on reversing global life-saving gains in the survival of childhood cancer: a call for collaborative action from SIOP, IPSO, PROS, WCC, CCI, St Jude Global, UICC and WHPCA. <i>Ecancermedalscience</i> , 2021, 15, 1187.	0.6	4
142	Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: Implications for retinoblastoma treatment. <i>Experimental Eye Research</i> , 2022, 218, 109026.	1.2	4
143	Second Neoplasms in Children Following a Treatment for Acute Leukemia and/or Lymphoma: 29 Years of Experience in a Single Institution in Argentina. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e406-e412.	0.3	3
144	Minimally disseminated disease and outcome in overt orbital retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27662.	0.8	3

#	ARTICLE	IF	CITATIONS
145	Comparison of the pharmacological activity of idarubicin and doxorubicin for retinoblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27441.	0.8	3
146	Metastatic retinoblastoma. , 2007, , 484-486.		3
147	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. <i>Journal of Pathology</i> , 2022, , .	2.1	3
148	Management of high-risk retinoblastoma. <i>Expert Review of Ophthalmology</i> , 2012, 7, 61-72.	0.3	2
149	Improved Outcome and Decreased Morbidity and Mortality Rates of B-Cell Malignancies with Less Intensive Chemotherapy Induction: Experience in a Single Institution. <i>Blood</i> , 2016, 128, 1858-1858.	0.6	2
150	SIOP Strategy 2021â€“2025: Cure for more, care for all. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29577.	0.8	2
151	Survivin is high in retinoblastoma, but what lies beneath?. <i>Journal of AAPOS</i> , 2018, 22, 482.	0.2	1
152	Retinoblastoma: an international perspective. , 2007, , 417-421.		1
153	Retinoblastoma: International Perspective. , 2015, , 51-60.		1
154	Impact of reactivation on the sequelae of multiâ€“system Langerhans cell histiocytosis patientsâ€™ response. <i>Pediatric Blood and Cancer</i> , 2008, 50, 932-932.	0.8	0
155	Pulmonary Manifestations of Hematologic and Oncologic Diseases. , 2009, , 135-169.		0
156	Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 574-581.	1.2	0
157	Retinoblastoma: Metastatic Disease. , 2019, , 249-253.		0
158	High prevalence of BRAF V600E in patients with cholestasis, sclerosing cholangitis or liver fibrosis secondary to Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29115.	0.8	0
159	Management of High-Risk Retinoblastoma. <i>Essentials in Ophthalmology</i> , 2015, , 85-96.	0.0	0
160	Retinoblastoma: An International Perspective. , 2019, , 57-65.		0